Literature DB >> 2508807

Determination of pravastatin sodium and its major metabolites in human serum/plasma by capillary gas chromatography/negative ion chemical ionization mass spectrometry.

P T Funke1, E Ivashkiv, M E Arnold, A I Cohen.   

Abstract

A capillary gas chromatography/negative ion chemical ionization mass spectrometry method has been developed to measure pravastatin sodium, an anti-hypercholesterolemic agent, and two of its major metabolites in human serum. Injected on a capillary column, derivatized pravastatin sodium and the two, metabolites were detected at levels of 0.5 pg microliters-1 injected with a signal-to-noise ratio of 3 to 1. The limit of detection was 0.3 ng ml-1 serum of each compound with 95% confidence using a weighted linear regression analysis. Prior to analysis, samples were purified on 200 mg C18 solid-phase extraction columns and derivatized with pentafluorobenzyl bromide and N,O-bis-(trimethylsilyl)-trifluoroacetamide. An excess of pentafluorobenzyl bromide was removed by reaction with propionic acid.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2508807     DOI: 10.1002/bms.1200181010

Source DB:  PubMed          Journal:  Biomed Environ Mass Spectrom        ISSN: 0887-6134


  8 in total

1.  Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin.

Authors:  H Y Pan; J Triscari; A R DeVault; S A Smith; D Wang-Iverson; B N Swanson; D A Willard
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

2.  Short-term effects of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor on cholesterol and bile acid synthesis in humans.

Authors:  T Yoshida; A Honda; J Shoda; M Abei; Y Matsuzaki; N Tanaka; H Miyazaki; T Osuga
Journal:  Lipids       Date:  1997-08       Impact factor: 1.880

Review 3.  Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.

Authors:  J P Desager; Y Horsmans
Journal:  Clin Pharmacokinet       Date:  1996-11       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events.

Authors:  T Hatanaka
Journal:  Clin Pharmacokinet       Date:  2000-12       Impact factor: 6.447

5.  Steady state serum concentrations of pravastatin and digoxin when given in combination.

Authors:  J Triscari; B N Swanson; D A Willard; A I Cohen; A Devault; H Y Pan
Journal:  Br J Clin Pharmacol       Date:  1993-09       Impact factor: 4.335

6.  A pharmacokinetic evaluation of pravastatin in middle-aged and elderly volunteers.

Authors:  S Sigurbjörnsson; T Kjartansdóttir; M Jóhannsson; J Kristinsson; G Sigurdsson
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Jan-Mar       Impact factor: 2.441

Review 7.  Clinical pharmacokinetics of pravastatin.

Authors:  J A Quion; P H Jones
Journal:  Clin Pharmacokinet       Date:  1994-08       Impact factor: 6.447

8.  Quantitative determination of pravastatin in pharmaceutical dosage forms by high-performance liquid chromatography with ultraviolet detection.

Authors:  Safwan Ashour; Husni Nakshbandi; Soulafa Omar
Journal:  Int J Biomed Sci       Date:  2008-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.